5-((dimethylamino)methyl)-N-(4-methoxybenzyl)pyridin-3-amine | 1428065-56-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-((dimethylamino)methyl)-N-(4-methoxybenzyl)pyridin-3-amine
• 英文别名: 5-[(dimethylamino)methyl]-N-[(4-methoxyphenyl)methyl]pyridin-3-amine
• CAS: 1428065-56-8
• 化学式: C₁₆H₂₁N₃O
• 分子量: 271.362
• InChiKey: XQFTYXCSZWCEIO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  37.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-((dimethylamino)methyl)-N-(4-methoxybenzyl)pyridin-3-amine 在 三氟乙酸 、 氨 、 chloroform methanol 、 silica gel 作用下， 以 三氟乙酸 为溶剂， 反应 1.0h， 以to afford 5-((dimethylamino)methyl)pyridin-3-amine (CIX) (0.044 g, 0.29 mmol, 52% yield) as a brown oil的产率得到5-((dimethylamino)methyl)pyridin-3-amine
  参考文献：
  名称：

  Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors

  摘要：

  本发明揭示了用于治疗各种疾病和病理的吲唑并[3,4-b]吲唑-3-甲酰胺化合物。更具体地，本发明涉及使用吲唑并[3,4-b]吲唑-3-甲酰胺化合物或其类似物来治疗通过激活Wnt通路信号（例如癌症、异常细胞增殖、血管生成和骨关节炎）特征的疾病，调节由Wnt通路信号介导的细胞事件，以及由于Wnt通路和/或一个或多个Wnt信号组分的突变或失调而导致的遗传疾病和神经系统疾病/紊乱/疾病。还提供了治疗Wnt相关疾病状态的方法。

  公开号：

  US08697887B2
• 作为产物：
  描述：

  5-溴吡啶-3-甲醛 在 tris-(dibenzylideneacetone)dipalladium(0) 、 caesium carbonate 、 三乙胺 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 5,5-dimethyl-1,3-cyclohexadiene 、 1,2-二氯乙烷 为溶剂， 反应 6.0h， 生成 5-((dimethylamino)methyl)-N-(4-methoxybenzyl)pyridin-3-amine
  参考文献：
  名称：

  5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF

  摘要：

  本文披露了用于治疗各种疾病和病理的吲唑化合物。更具体地，本公开涉及使用吲唑化合物或其类似物来治疗通过激活Wnt通路信号特征的疾病（例如癌症、异常细胞增殖、血管生成、阿尔茨海默病、肺部疾病、纤维化疾病、软骨（软骨）缺陷和骨关节炎），调节由Wnt通路信号介导的细胞事件，以及与DYRK1A过表达相关的神经系统状况/障碍/疾病。

  公开号：

  US20150266825A1

文献信息

• [EN] INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS<br/>[FR] INDAZOLE-3-CARBOXAMIDES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA VOIE DE SIGNALISATION PAR WNT/Beta-CATÉNINE
  申请人：SAMUMED LLC

  公开号：WO2013040215A1

  公开（公告）日：2013-03-21

  lndazole-3-carboxamide compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole-3- carboxamide compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

  本文披露了用于治疗各种疾病和病理的吲唑-3-羧酰胺化合物。更具体地，本文涉及使用吲唑-3-羧酰胺化合物或其类似物治疗由Wnt途径信号激活所特征的疾病（例如癌症、异常细胞增殖、血管生成和骨关节炎），调节由Wnt途径信号介导的细胞事件，以及由于Wnt途径和/或Wnt信号组分之一或多个的突变或失调而引起的遗传疾病和神经系统疾病/紊乱/疾病。还提供了治疗与Wnt相关疾病状态的方法。
• 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF
  申请人：Samumed, LLC

  公开号：US20150266825A1

  公开（公告）日：2015-09-24

  Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, fibrotic disorders, cartilage (chondral) defects, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, and neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

  本文披露了用于治疗各种疾病和病理的吲唑化合物。更具体地，本公开涉及使用吲唑化合物或其类似物来治疗通过激活Wnt通路信号特征的疾病（例如癌症、异常细胞增殖、血管生成、阿尔茨海默病、肺部疾病、纤维化疾病、软骨（软骨）缺陷和骨关节炎），调节由Wnt通路信号介导的细胞事件，以及与DYRK1A过表达相关的神经系统状况/障碍/疾病。
• INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/BETA-CATENIN SIGNALING PATHWAY INHIBITORS
  申请人：Samumed, LLC

  公开号：US20140045815A1

  公开（公告）日：2014-02-13

  Indazole-3-carboxamide compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole-3-carboxamide compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

  本发明揭示了用于治疗各种疾病和病理的吲唑并[3,2-c]吡唑-3-羧酰胺化合物。更具体地，本发明涉及使用吲唑并[3,2-c]吡唑-3-羧酰胺化合物或其类似物，治疗由Wnt通路信号激活引起的疾病（例如癌症，异常细胞增殖，血管生成和骨关节炎），调节由Wnt通路信号介导的细胞事件，以及由于Wnt通路和/或Wnt信号组分之一或多个的突变或失调引起的遗传疾病和神经系统疾病/疾病/病症。还提供了治疗Wnt相关疾病状态的方法。
• INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/Beta-CATENIN SIGNALING PATHWAY INHIBITORS
  申请人：Hood John

  公开号：US20130079329A1

  公开（公告）日：2013-03-28

  Indazole-3-carboxamide compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole-3-carboxamide compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

  本发明公开了用于治疗各种疾病和病理的吲唑并[3,2-c]异噁唑-3-羧酰胺化合物。更具体地，本发明涉及使用吲唑并[3,2-c]异噁唑-3-羧酰胺化合物或其类似物，治疗由Wnt途径信号激活引起的疾病（例如癌症、异常细胞增殖、血管生成和骨关节炎），调节由Wnt途径信号介导的细胞事件，以及由Wnt途径和/或一个或多个Wnt信号传导组分的突变或失调引起的遗传疾病和神经系统疾病/障碍/疾病的方法。还提供了治疗Wnt相关疾病状态的方法。
• Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors
  申请人：Samumed, LLC

  公开号：US08697887B2

  公开（公告）日：2014-04-15

  Indazole-3-carboxamide compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole-3-carboxamide compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

  本发明揭示了用于治疗各种疾病和病理的吲唑并[3,4-b]吲唑-3-甲酰胺化合物。更具体地，本发明涉及使用吲唑并[3,4-b]吲唑-3-甲酰胺化合物或其类似物来治疗通过激活Wnt通路信号（例如癌症、异常细胞增殖、血管生成和骨关节炎）特征的疾病，调节由Wnt通路信号介导的细胞事件，以及由于Wnt通路和/或一个或多个Wnt信号组分的突变或失调而导致的遗传疾病和神经系统疾病/紊乱/疾病。还提供了治疗Wnt相关疾病状态的方法。